Synthetic biology startup Codon Devices of Cambridge, MA, announced today that it has reached a settlement with Blue Heron Biotechnology of Bothell, WA, in a patent suit that Codon filed against the Washington firm last March. The suit involved five patents that were exclusively licensed to Codon—one from MIT and four from Duke University. As part of the agreement, financial terms of which were not disclosed, Codon has granted Blue Heron a sublicense on the technology.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
